These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35630075)

  • 21. Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration.
    Habibi I; Kort F; Sfar I; Chebil A; Bouraoui R; Ben Abdallah T; Gorgi Y; El Matri L
    Klin Monbl Augenheilkd; 2016 Apr; 233(4):465-70. PubMed ID: 27116510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.
    Tsuchihashi T; Mori K; Horie-Inoue K; Gehlbach PL; Kabasawa S; Takita H; Ueyama K; Okazaki Y; Inoue S; Awata T; Katayama S; Yoneya S
    Ophthalmology; 2011 Jan; 118(1):93-100. PubMed ID: 20678803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.
    Lee AY; Raya AK; Kymes SM; Shiels A; Brantley MA
    Br J Ophthalmol; 2009 May; 93(5):610-3. PubMed ID: 19091853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
    Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y
    Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.
    Feng X; Xiao J; Longville B; Tan AX; Wu XN; Cooper MN; McAllister IL; Isaacs T; Palmer LJ; Constable IJ
    Ophthalmology; 2009 Oct; 116(10):1908-12.e1. PubMed ID: 19692124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The genetic variant rs4073 A→T of the Interleukin-8 promoter region is associated with the earlier onset of exudative age-related macular degeneration.
    Hautamäki A; Seitsonen S; Holopainen JM; Moilanen JA; Kivioja J; Onkamo P; Järvelä I; Immonen I
    Acta Ophthalmol; 2015 Dec; 93(8):726-33. PubMed ID: 26154559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between polymorphisms of complement pathway genes and age-related macular degeneration in a Chinese population.
    Wu L; Tao Q; Chen W; Wang Z; Song Y; Sheng S; Li P; Zhou J
    Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):170-4. PubMed ID: 23233260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography.
    Teper SJ; Nowinska A; Pilat J; Wylegala E
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():108-113. PubMed ID: 26780119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.
    Dikmetas O; Kadayıfcılar S; Eldem B
    Mol Vis; 2013; 19():2571-8. PubMed ID: 24367156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
    Kang HK; Yoon MH; Lee DH; Chin HS
    Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.
    Chen H; Yu KD; Xu GZ
    PLoS One; 2012; 7(8):e42464. PubMed ID: 22905135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.
    Wegscheider BJ; Weger M; Renner W; Steinbrugger I; März W; Mossböck G; Temmel W; El-Shabrawi Y; Schmut O; Jahrbacher R; Haas A
    Ophthalmology; 2007 Apr; 114(4):738-42. PubMed ID: 17398321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Y402H polymorphism in complement factor H and age-related macular degeneration in the Tunisian population.
    Habibi I; Sfar I; Kort F; Aounallah-Skhiri H; Chebil A; Chouchene I; Bouraoui R; Limaiem R; Largheche L; Jendoubi-Ayed S; Makhlouf M; Ben Abdallah T; Ayed K; El Matri L; Gorgi Y
    Ophthalmic Res; 2013; 49(4):177-84. PubMed ID: 23306536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of
    Cebatoriene D; Vilkeviciute A; Gedvilaite-Vaicechauskiene G; Duseikaite M; Bruzaite A; Kriauciuniene L; Zaliuniene D; Liutkeviciene R
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.
    Maguire MG; Daniel E; Shah AR; Grunwald JE; Hagstrom SA; Avery RL; Huang J; Martin RW; Roth DB; Castellarin AA; Bakri SJ; Fine SL; Martin DF;
    Ophthalmology; 2013 Oct; 120(10):2035-41. PubMed ID: 23706946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population.
    Liu X; Zhao P; Tang S; Lu F; Hu J; Lei C; Yang X; Lin Y; Ma S; Yang J; Zhang D; Shi Y; Li T; Chen Y; Fan Y; Yang Z
    Retina; 2010 Sep; 30(8):1177-84. PubMed ID: 20523265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of CC-cytokine ligand 2 and complementary factor H Y402H polymorphisms and their interactional association with age-related macular degeneration.
    Bonyadi M; Foruzandeh Z; Mohammadian T; Fotouhi N; Soheilian M; Jabbarpoor Bonyadi MH; Javadzadeh A; Moein H; Yaseri M
    Acta Ophthalmol; 2016 Dec; 94(8):e779-e785. PubMed ID: 27316788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Wang VM; Rosen RB; Meyerle CB; Kurup SK; Ardeljan D; Agron E; Tai K; Pomykala M; Chew EY; Chan CC; Tuo J
    Mol Vis; 2012; 18():2578-85. PubMed ID: 23112570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
    Orlin A; Hadley D; Chang W; Ho AC; Brown G; Kaiser RS; Regillo CD; Godshalk AN; Lier A; Kaderli B; Stambolian D
    Retina; 2012 Jan; 32(1):4-9. PubMed ID: 21878851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.